Skip to main content
Figure 2 | BMC Infectious Diseases

Figure 2

From: A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine

Figure 2

Incidence and 95%CI of solicited local and general symptoms recorded during the 7-day post-vaccination follow-up period (Total vaccinated cohort). Group definitions: Group A: TIV+Placebo (Day 0); 15 μg (Day 21); 15 μg (Day 42); Group B: TIV+Placebo (Day 0); 3.75 μg/AS03 (Day 21); 3.75 μg/AS03 (Day 42); Group C: 15 μg+TIV (Day 0); 15 μg (Day 21); Placebo (Day 42); Group D: 3.75 μg/AS03+TIV (Day 0); 3.75 μg/AS03 (Day 21); Placebo (Day 42); Group E: 15 μg+Placebo (Day 0); 15 μg (Day 21); TIV (Day 42); Group F: 3.75 μg/AS03+Placebo (Day 0); 3.75 μg/AS03 (Day 21); TIV (Day 42).

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us